



MARKET RELEASE

13 June 2012

Bioxyne Limited

TRADING HALT

The securities of Bioxyne Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 15 June 2012 or when the announcement is released to the market.

Security Code: BXN

Kimberley Brown
Senior Adviser, Listings (Sydney)



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



Ms Kimberley Brown
Senior Adviser, Listing
Australian Securities Exchange Limited
SYDNEY

12 June, 2012

Request for Trading Halt

In accordance with ASX Listing Rule 17.1, Bioxyne Limited ("Company") requests the granting of a trading halt in Bioxyne's ordinary securities (ASX code: BXN) listed on ASX from the commencement of trading on 13 June 2012 to close of business on 14 June 2012 (48 hours) due to the following reasons:

- 1) The Company will receive results from the Phase IIB study on 13 June 2012 from its independent Clinical Research Organisation (CRO). These results will be an extensive review of both primary and secondary results which require significant interpretation. Incorrect interpretation could result in a significant share price movement both positive and negative.
- 2) Under the ASX continuous disclosure requirements, it is the Company's intention to provide clear, and factually correct information to our shareholders, which enables them to make a fully informed investment decision. Given the volume of this data, it is critical that Company has time to adequately assess and understand the data without the pressure of speculative trading in the stock, or the risk of information leaking to the market in an uncontrolled fashion.

The Company confirms that it is not aware of any reason why a trading halt should not be granted.

Yours faithfully
Ashok Jairath
Company Secretary



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



About Bioxyne

Bioxyne Limited (ASX:BNE) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV, in Phase IIb clinical trials for Chronic Obstructive Pulmonary Disease (COPD), works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. The results of the Phase IIb clinical study into the safety and efficacy of HI-164OV are expected mid 2012. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit www.bioxyne.com